Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Knutson

Showing results (31-40 of 147) with videos related to

Pageof 15
Sort By:
Journal of Hematology & Oncology|January 14, 2018
Cancer immunotherapy beyond immune checkpoint inhibitorsJulian A Marin-Acevedo, Aixa E Soyano, Bhagirathbhai Dholaria, et al.
Critical Reviews in Immunology|April 16, 2013
The immune system in the pathogenesis of ovarian cancerBridget Charbonneau, Ellen L Goode, Kimberly R Kalli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 28, 2012
Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cellsAndrea M Henle, Courtney L Erskine, Linda M Benson, et al.
Cancers|May 27, 2026
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical ImplementationPanuch Eiamprapaporn, Cindy Venegas Mata, Raj Nandani, et al.
Breast Cancer Research and Treatment|November 10, 2009
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cellsJohanna K Morales, Maciej Kmieciak, Keith L Knutson, et al.
Immunotherapy|April 6, 2011
Immunity and immune suppression in human ovarian cancerClaudia C Preston, Ellen L Goode, Lynn C Hartmann, et al.
Cancer Research|May 11, 2011
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotypeMichael K Asiedu, James N Ingle, Marshall D Behrens, et al.
Journal of Hematology & Oncology|March 17, 2018
Next generation of immune checkpoint therapy in cancer: new developments and challengesJulian A Marin-Acevedo, Bhagirathbhai Dholaria, Aixa E Soyano, et al.
Research Square|April 22, 2024
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanomaEmmanuel M Gabriel, Brian Necela, Deborah Bahr, et al.
Scientific Reports|October 19, 2024
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanomaEmmanuel M Gabriel, Brian Necela, Deborah Bahr, et al.
Pageof 15

Showing results (31-40 of 147) with videos related to

Sort By:
Pageof 15
Journal of Hematology & Oncology|January 14, 2018
Cancer immunotherapy beyond immune checkpoint inhibitorsJulian A Marin-Acevedo, Aixa E Soyano, Bhagirathbhai Dholaria, et al.
Critical Reviews in Immunology|April 16, 2013
The immune system in the pathogenesis of ovarian cancerBridget Charbonneau, Ellen L Goode, Kimberly R Kalli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 28, 2012
Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cellsAndrea M Henle, Courtney L Erskine, Linda M Benson, et al.
Cancers|May 27, 2026
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical ImplementationPanuch Eiamprapaporn, Cindy Venegas Mata, Raj Nandani, et al.
Breast Cancer Research and Treatment|November 10, 2009
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cellsJohanna K Morales, Maciej Kmieciak, Keith L Knutson, et al.
Immunotherapy|April 6, 2011
Immunity and immune suppression in human ovarian cancerClaudia C Preston, Ellen L Goode, Lynn C Hartmann, et al.
Cancer Research|May 11, 2011
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotypeMichael K Asiedu, James N Ingle, Marshall D Behrens, et al.
Journal of Hematology & Oncology|March 17, 2018
Next generation of immune checkpoint therapy in cancer: new developments and challengesJulian A Marin-Acevedo, Bhagirathbhai Dholaria, Aixa E Soyano, et al.
Research Square|April 22, 2024
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanomaEmmanuel M Gabriel, Brian Necela, Deborah Bahr, et al.
Scientific Reports|October 19, 2024
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanomaEmmanuel M Gabriel, Brian Necela, Deborah Bahr, et al.
Pageof 15